TBCA

TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases.

Product information

CAS Number: 934358-00-6

Molecular Weight: 463.74

Formula: C9H4Br4O2

Chemical Name: (2E)-3-(2, 3, 4, 5-tetrabromophenyl)prop-2-enoic acid

Smiles: OC(=O)/C=C/C1=CC(Br)=C(Br)C(Br)=C1Br

InChiKey: SVJQCVOKYJWUBC-OWOJBTEDSA-N

InChi: InChI=1S/C9H4Br4O2/c10-5-3-4(1-2-6(14)15)7(11)9(13)8(5)12/h1-3H,(H,14,15)/b2-1+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: 2mg/ml in DMSO;5mg/ml in dimethyl formamide

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

TBCA (0-100 μM; 24 hours) shows a drastic effect on Jurkat cells viability. TBCA also inhibits CK2 double mutant (Val66 Ile174) with an IC50 of 0.68 μM. TBCA dose-dependently inhibits platelet aggregation and secretion induced by various agonists including 2-MeSADP, AYPGKF, SFLLRN, and CRP. TBCA also inhibits phosphorylation of PDK1, Akt, and GSK3β induced by AYPGKF.

References:

1. Pagano MA, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007;8(1):129-139.
2. Ryu SY, Kim S. Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013;720(1-3):391-400.

Products are for research use only. Not for human use.